KCT0005636招募中未知
A Phase 2, Open-Label Study of Orally Administered PAX-1 Therapy in Patients with Brain Metastases (BM) Secondary to Non-Small Cell Lung Cancer (NSCLC)
ovotech Asia Korea0 个研究点目标入组 76 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 76
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional Study
入排标准
- 年龄范围
- 18?(Year) 至 0No Limit（—）
- 性别
- All
入选标准
- •Inclusion Criteria:
- •All patients enrolling into the study must meet all the following inclusion criteria:
- •1.Willing to sign written informed consent
- •2.Histological or cytological confirmation advanced NSCLC (stage IV) with radiologically documented BM. Contrast-enhanced magnetic resonance imaging (MRI) or computed tomography (CT) confirmed BM with at least one measurable lesion (according to RANO -BM and RECIST v1.1)
- •3. Patients with asymptomatic BM secondary to NSCLC who are intolerant to standard treatment or resistant to standard therapy (per NCCN guidelines) or for whom curative therapy is no longer an option
- •4. Age = 18 years at time of study entry (or age of legal consent, whichever is older)
- •5. ECOG performance status = 2 i.e., 0, 1 or 2
- •6. Body weight >30kg
- •7.Life expectancy of at least 3 months
- •8.Adequate hematology laboratory data within 6 weeks prior to start of treatment: absolute neutrophils > 1.5 x 10 9/L, platelets = 100 x 109/L, hemoglobin = 9 g/dL
- •9. Adequate biochemistry laboratory data within 6 weeks prior to start of treatment: Total bilirubin = 1.5 x upper limit of normal (ULN) (except patient with confirmed Gilbert's syndrome or liver metastasis: total bilirubin = 3 ULN), transaminases = 2.5 x ULN or = 5.0 x ULN for patients with documented liver metastases, alkaline phosphatases = 5 x ULN, creatinine clearance > 40 mL/min (Cockcroft), albumin > 24 g/L, serum magnesium 0.70~1.10 mmol/L, serum potassium 3.5~5.2 mmol/L
- •10.Women should be post-menopausal or willing to accept the use of an effective contraceptive regimen during the treatment period and at least 3 months after the end of the study treatment. All non-menopausal women should have a negative pregnancy test within 72 hours prior to registration. Men should accept to use an effective contraception during treatment period and at least 3 months after the end of the study treatment
- •11.Patient willing and able to comply with the protocol for the duration of the study including undergoing treatment and examinations including follow-up as per scheduled visits
排除标准
- •Exclusion Criteria:
- •Any of the following criteria will exclude patients from study participation:
- •1. Central nervous system (CNS) complications for which urgent neurosurgical intervention is indicated (e.g., resection, shunt placement)
- •2. Known leptomeningeal metastases
- •3.Patient unable to have MRI or CT for any reason (e.g., due to pacemaker, ferromagnetic implants, claustrophobia, extreme obesity, allergic reactions to contrast agents used for CT)
- •4.Known history of elevated risks for torsade de point (TdP), such as hyperkalemia, or family history of long QT syndrome.
- •5.Any of the following cardiac abnormalities:
- •Unstable angina pectoris,
- •Congestive heart failure = New York Heart Association (NYHA) Class 3, or
- •ECG evidence of a QT interval with Frederica’s correction (QTcF) > 450 ms in males and > 470 ms in females
- •6.Any unresolved toxicity National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) Grade =2 from previous anticancer therapy with the exception of alopecia, vitiligo, and the laboratory values defined in the inclusion criteria
- •7.Participation in another therapeutic trial within the 30 days prior to entering this study (participation in a survival follow -up period of a clinical study is not an exclusion criterion)
- •8.Patients known or suspected to have hypersensitivities, allergies to sodium meta-arsenite, related compounds or any of the excipients of the IP
- •9.Current or prior use of immunosuppressive medication within 14 days before the first fraction of RT (exception: systemic corticosteroids at physiologic doses not exceeding 10 mg/day of prednisone or equivalent are allowed as well as steroids as premedication for hypersensitivity reactions (e.g., CT scan premedication) -Topical, inhaled, nasal and ophthalmic steroids are not prohibited).
- •10.Known primary immunodeficiency or active human immunodeficiency virus (HIV) (positive HIV 1/2 antibodies)
- •11.Known active or chronic viral hepatitis or history of any type of hepatitis within the last 6 months indicated by positive test for hepatitis B surface antigen (HBsAg) or hepatitis C virus (HCV) anti body test
- •12. History of active tuberculosis (TB) (clinical evaluation that includes clinical history, physical examination and radiographic findings, and TB testing in-line with local practice)
- •13. Female patients who are pregnant or breastfeeding or male or female patients of reproductive potential who are not willing to employ effective birth control from screening to 90 days after the last dose of IP
- •14. Patients with an inability to comply with study procedures or any condition which in the Investigator's opinion makes the patient unsuitable for study participation.
- •15. History or evidence of any other clinically significant condition that, in the opinion of the Investigator, would pose a risk to patient safety or interfere with study procedures, evaluation or completion.
- •16. Inability to swallow oral medications or pre-existing gastrointestinal disorders that might interfere with proper absorption of oral drugs.
研究者
相似试验
已完成
2 期
A Phase 2, open label study of orally administered PAX-1 monotherapy in patients with recurrent glioblastoma.Cancer - BrainGlioblastomaACTRN12619000640101ovotech (Australia) Pty Limited40
进行中（未招募）
不适用
An open label two-stage study of orally administered BKM120 in patients with metastatic non-small cell lung cancer with activated PI3K pathwayAdult patients with metastatic NSCLC with activated PI3Kpathway.MedDRA version: 14.0Level: PTClassification code 10059515Term: Non-small cell lung cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2010-024011-14-DEovartis Pharma Services AG180
招募中
2 期
An open label two-stage study of orally administered BKM120 in patients with metastatic non-small cell lung cancer with activated PI3K pathway.lungcancerMetastatic non small cell lung cancer10029107NL-OMON38313ovartis100
进行中（未招募）
不适用
An open label two-stage study of orally administered BKM120 in patients with metastatic non-small cell lung cancer with activated PI3K pathwayAdult patients with metastatic NSCLC with activated PI3Kpathway.MedDRA version: 14.1Level: PTClassification code 10059515Term: Non-small cell lung cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2010-024011-14-BEovartis Pharma Services AG180
进行中（未招募）
不适用
未命名试验Metastatic non-small cell lung cancer (NSCLC) with activated PI3K pathway.MedDRA version: 14.0Level: PTClassification code 10059515Term: Non-small cell lung cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2010-024011-14-ITOVARTIS FARMA180